低剂量伐昔洛韦治疗带状疱疹眼病研究中的带状疱疹后神经痛:一项随机临床试验
这项多中心、安慰剂对照随机临床试验纳入527例带状疱疹眼病(HZO)患者,比较口服伐昔洛韦1000 mg/d与安慰剂治疗12个月对带状疱疹后神经痛(PHN)的影响。12个月时PHN患病率在伐昔洛韦组为38%(12/32),安慰剂组为40%(14/35),组间差异2.5%(95%CI -20.8%至25.8%;P>.99),未显示降低。两组在疼痛评分、疼痛持续时间和每日神经痛药物总剂量等次要结局上存在差异,作者认为这些次要结局支持考虑1年抑制性伐昔洛韦治疗以减少疼痛药物剂量和HZO所致疼痛。
要点
- 12个月时PHN患病率伐昔洛韦组38%(12/32)vs 安慰剂组40%(14/35),组间差异2.5%(95%CI -20.8%至25.8%;P>.99)。
- HZO发病时<60岁且病程为慢性的参与者,12个月疼痛评分伐昔洛韦组0.3(SD 0.9)vs 安慰剂组0.8(SD 1.9)(P=.045)。
- 18个月疼痛持续时间伐昔洛韦组13.6(SD 11.4)个月vs 安慰剂组18.7(SD 29.5)个月,组间差异-3.39个月(95%CI -6.73至-0.04;P=.046)。
核心结论
- 1年抑制性伐昔洛韦治疗与较低的神经痛药物剂量相关。
- 伐昔洛韦组中HZO发病时较年轻且病程为慢性的参与者疼痛评分较低。
- 这些次要结局支持考虑1年抑制性伐昔洛韦治疗以减少疼痛药物剂量和HZO所致疼痛。
研究设计与样本
- 多中心、安慰剂对照随机临床试验,纳入527例免疫功能正常、非妊娠成人,有HZO皮疹史、记录到角膜炎或虹膜炎且在1年内,估算肾小球滤过率≥45 mL/min/1.73 m2。
- 研究在95个参与中心(加拿大、新西兰和美国)于2017年11月至2024年6月进行,参与者每3个月随访一次。
- 干预为伐昔洛韦1000 mg/d或安慰剂治疗12个月。
主要发现
- 527例参与者中490例完成12个月治疗、460例完成18个月;73例(14%)有PHN,其中伐昔洛韦组34例、安慰剂组39例,平均年龄62.4岁(SD 13.6),59%为女性,5%为黑人或非裔美国人,10%为西班牙裔。
- 12个月时PHN患病率伐昔洛韦组38%(12/32)vs 安慰剂组40%(14/35),组间差异2.5%(95%CI -20.8%至25.8%;P>.99)。
- HZO发病时<60岁且病程为慢性的参与者,12个月疼痛评分伐昔洛韦组0.3(SD 0.9)vs 安慰剂组0.8(SD 1.9)(P=.045);18个月分别为0.2(SD 0.9)vs 1.0(SD 2.3)(P=.02)。
- 18个月疼痛持续时间伐昔洛韦组13.6(SD 11.4)个月vs 安慰剂组18.7(SD 29.5)个月,线性混合效应模型组间差异-3.39个月(95%CI -6.73至-0.04;P=.046)。
- 每日神经痛药物总剂量12个月时伐昔洛韦组271.4(SD 593.8)mg/d vs 安慰剂组363.4(SD 592.2)mg/d(线性混合效应模型P=.006);18个月时分别为209.0(SD 412.8)mg/d vs 286.2(SD 577.9)mg/d(线性混合效应模型P=.01)。
关键数值与推荐
- PHN定义为疼痛评分≥3分(1-10分量表)、HZO发病后疼痛持续≥3个月。
- 主要结局为PHN患病率、严重程度(疼痛评分)、疼痛持续时间和每日疼痛药物总剂量。
临床怎么用
- 作者认为次要结局支持考虑1年抑制性伐昔洛韦治疗以减少疼痛药物剂量和HZO所致疼痛。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Evidence regarding suppressive valacyclovir treatment on postherpetic neuralgia is necessary to guide care. OBJECTIVE: To test the hypothesis that suppressive treatment with 1000 mg/d of oral valacyclovir for 12 months reduces the prevalence, severity, and duration of postherpetic neuralgia compared with placebo at 12 and 18 months in participants with herpes zoster ophthalmicus (HZO). DESIGN, SETTING, AND PARTICIPANTS: Multicenter, placebo-controlled randomized clinical trial including 527 immunocompetent, nonpregnant adults with history of HZO rash, documented keratitis, or iritis within 1 year and an estimated glomerular filtration rate of 45 mL/min/1.73 m2 or greater. The study was conducted at 95 participating sites (in Canada, New Zealand, and the US) from November 2017 to June 2024 and participant visits occurred every 3 months. INTERVENTION: Treatment with 1000 mg/d of valacyclovir or placebo for 12 months. MAIN OUTCOMES AND MEASURES: Prevalence of postherpetic neuralgia, severity as determined by pain score (a score of ≥3 on a scale of 1-10), pain duration (≥3 months after HZO onset), and total daily dose of pain medication. RESULTS: Of the 527 participants (490 completed 12 months of treatment and 460 completed 18 months), 73 (14%) had postherpetic neuralgia and were analyzed by age at HZO onset (<60 years or ≥60 years) and disease duration (recent [<6 months] or chronic [≥6 months]). Of the 73 participants with postherpetic neuralgia (34 in the valacyclovir group and 39 in the placebo group), the mean age was 62.4 years (SD, 13.6 years), 59% were female, 5% were Black or African American, and 10% were Hispanic. The prevalence of postherpetic neuralgia at 12 months was not reduced by valacyclovir (12/32 [38%]) compared with placebo (14/35 [40%]) (between-group difference, 2.5% [95% CI, -20.8% to 25.8%]; P>.99). The participants who were younger than 60 years at HZO onset and had a chronic disease duration had lower pain scores in the valacyclovir group (mean score, 0.3 [SD, 0.9]) vs the placebo group (mean score, 0.8 [SD, 1.9]) at 12 months (P = .045) and at 18 months (mean score, 0.2 [SD, 0.9] vs 1.0 [SD, 2.3], respectively; P = .02). There was a decrease in pain duration in the valacyclovir group at 18 months (mean, 13.6 [SD, 11.4] months) vs the placebo group (mean, 18.7 [SD, 29.5] months) (linear mixed-effects model between-group difference, -3.39 months [95% CI, -6.73 to -0.04 months]; P = .046). The total daily dose of neuropathic pain medication was lower in the valacyclovir group (mean, 271.4 [SD, 593.8] mg/d) vs the placebo group (mean, 363.4 [SD, 592.2] mg/d) at 12 months (linear mixed-effects model P = .006) and at 18 months (mean, 209.0 [SD, 412.8] mg/d vs 286.2 [SD, 577.9] mg/d, respectively; linear mixed-effects model P = .01). CONCLUSIONS AND RELEVANCE: One year of suppressive treatment with valacyclovir was associated with a lower dosage of neuropathic pain medication. Participants in the valacyclovir group, who were younger at HZO onset and had a chronic disease duration, had lower pain scores. These secondary outcomes support consideration of 1 year of suppressive treatment with valacyclovir to reduce dosage of pain medications and pain due to HZO. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03134196.
引用
- Warner DB, Jeng BH, Kim J, et al. Low-Dose Valacyclovir for Postherpetic Neuralgia in the Zoster Eye Disease Study: A Randomized Clinical Trial. JAMA Ophthalmol. 2025. PMID: 40048191. doi:10.1001/jamaophthalmol.2024.6113
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。